Bellicum - Articles and news items

Bellicum recommended for $16.9 million Texan cancer research award

Industry news / 22 November 2016 / Niamh Louise Marriott, Digital Content Producer

The Institute of Texas award would fund a 3 year global clinical program of clinical trials for adult and paediatric patients acute myeloid leukaemia…

EU approval in sight as Bellicum’s BPX-501 granted orphan drug designation

Industry news / 5 August 2016 / Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, a clinical stage biopharmaceutical company, has been granted orphan drug designations for both its T-cell therapy product candidate BPX-501 for treatment in hematopoietic stem cell transplantation (HSCT), and for activator agent rimiducid…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+